ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Adaptimmune Therapeutics PLC revenue by segment
By business segment
By product or service
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Development revenue | $176.80M | $60.28M | $27.15M | $6.15M | $3.96M | $1.12M | $20.39M | – | – | – | 99.3% | +193.3% |
| Product revenue, net | $1.24M | – | – | – | – | – | – | – | – | – | 0.7% | – |
| Development revenue | – | – | – | – | $3.96M | $1.12M | $20.39M | $37.83M | – | – | – | – |
| License revenue | – | – | – | – | – | – | $39.11M | – | – | – | – | – |
| License revenue | – | – | – | – | – | – | $39.11M | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Adaptimmune Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.